- Details
- Currently, the standard of care for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy. Patients with residual disease after neoadjuvant chemotherapy have an especially poor prognosis. Unfortunately, there's no standard adjuvant therapy for these patients. Andrew Lenis joins Ashish Kamat emphasizing that additional therapeutic options are needed, and understa...
|
- Details
- Alfred Witjes, MD, PhD, a member of the international multidisciplinary panel of bladder cancer experts for the European Association of Urology (EAU) Guidelines on muscle-invasive and metastatic bladder cancer joins Ashish Kamat, MD, MBBS, in a discussion summarizing the 2020 updated guidelines. Professor Witjes highlights several updates including variant histologies, the best surgical approach f...
|
- Details
- Cisplatin-based chemotherapy is recommended in both the neoadjuvant and the first-line setting. The inability to predict which patients would respond to chemotherapy, presents a major clinical problem, as there is a significant overtreatment of patients who do not respond. Lars Dyrskjøt joins Ashish Kamat to discuss a Nature Communications publication titled, Molecular correlates of cisplatin-base...
|
- Details
- The anti-PD-L1 avelumab in urothelial carcinoma—A discussion with investigator Dr Andrea Apolo. The JAVELIN Solid Tumor phase 1, open-label, dose-escalation trial investigated avelumab, a human monoclonal anti-PD-L1 antibody (anti-PD-L1), in patients with selected tumor indications (eg, NSCLC, breast cancer, colorectal cancer). Pooled analysis of two JAVELIN cohorts that included patients with adv...
|
- Details
- Beyond Endpoints: An interview with Dr Srikala Sridhar, study chair of the BL12 trial Investigator-initiated trials (IITs) often tackle important questions that are not addressed elsewhere. [transcript] Compared with a pharmaceutical company–managed trials, benefits of IITs include generating data in a real-world setting and resolving issues that confound physicians in daily practice. A recent ope...
|
- Details
- Black individuals with muscle-invasive bladder cancer (MIBC) experience 21% lower odds of guideline-based treatment (GBT). Differences in treatment account for 35% of observed Black-White differences in survival. Samuel Washington III, MD, MAS joins Ashish Kamat, MD, MBBS, to highlight this data published in Cancer Medicine. Low GBT levels demonstrated an "under-allocation" of GBT to those who nee...
|
- Details
- Michiel Van der Heijden MD, PhD, joins Ashish Kamat, MD, MBBS discussing the evolution of the guidelines for advanced urothelial cancer. Michiel Van der Heijden provides a concise summary of the European Association of Urology Guidelines and the ESMO guidelines, contrasting statements between the two for patients in first-line treatment who are ineligible to receive cisplatin-based chemotherapy in...
|
- Details
- Guru Sonpavde joins Alicia Morgans, MD, MPH in a discussion on the treatment landscape of muscle-invasive bladder cancer and several trials that could lead to changes in treatment patterns across the bladder cancer disease spectrum. They review data recently presented at the 2020 European Society for Medical Oncology Virtual Congress, (ESMO) including sacituzumab govitecan in Cohort 3 of the TROPH...
|
- Details
- The identification of predictive biomarkers for immunotherapy response is an area of intense research interest. In this conversation with Alicia Morgans, MD, MPH, Srikala Sridhar MD, MSc, FRCPC highlights her presentation from the European Society for Medical Oncology (ESMO) 2020 virtual meeting. At this meeting, Dr. Sridhar presented an assessment of potential biomarkers for response within the J...
|
- Details
- Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH highlighting promising data from a different antibody-drug conjugate called sacituzumab govitecan (IMMU-132). There are a number of ongoing studies where sacituzumab govitecan which is being studied in advanced bladder cancer. Enfortumab vedotin targets Nectin-4, while sacituzumab govitecan is targeting Trop-2. Dr. Grivas highlights the final r...
|
